Human monoclonal antibodies derived from lymph nodes of a patient with breast carcinoma react with MuMTV polypeptides

Shoenfeld, Yehuda; Hizi, Amnon; Tal, Raanan; Smorodinsky, Nechama I.; Lavie, Gad; C, Mor; Schteren, Sidi; Mammon, Zipora; Pinkhas, J; Keydar, Tafa

doi:10.1002/1097-0142(19870101)59:1<43::aid-cncr2820590113>3.0.co;2-3

Cited by 21 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 Subsequent laboratory work showed the ability of hormone-dependent cells to undergo repeated cycles of apoptosis secondary to cyclic hormonal withdrawal. Bruchovsky et al 6 used the androgen-dependent Shionogi carcinoma as a model to suggest that castration followed by reexposure to androgens before tumor progression preserved androgen dependence in surviving stem cells, leaving them amenable to further androgen withdrawal.…”

mentioning

confidence: 99%

Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy

et al. 2012

View full text Add to dashboard Cite

BACKGROUND Intermittent androgen deprivation for prostate-specific antigen (PSA) elevation after radiotherapy may improve quality of life and delay hormone resistance. We assessed overall survival with intermittent versus continuous androgen deprivation in a noninferiority randomized trial. METHODS We enrolled patients with a PSA level greater than 3 ng per milliliter more than 1 year after primary or salvage radiotherapy for localized prostate cancer. Intermittent treatment was provided in 8-month cycles, with nontreatment periods determined according to the PSA level. The primary end point was overall survival. Secondary end points included quality of life, time to castration-resistant disease, and duration of nontreatment intervals. RESULTS Of 1386 enrolled patients, 690 were randomly assigned to intermittent therapy and 696 to continuous therapy. Median follow-up was 6.9 years. There were no significant between-group differences in adverse events. In the intermittent-therapy group, full testosterone recovery occurred in 35% of patients, and testosterone recovery to the trial-entry threshold occurred in 79%. Intermittent therapy provided potential benefits with respect to physical function, fatigue, urinary problems, hot flashes, libido, and erectile function. There were 268 deaths in the intermittent-therapy group and 256 in the continuous-therapy group. Median overall survival was 8.8 years in the intermittent-therapy group versus 9.1 years in the continuous-therapy group (hazard ratio for death, 1.02; 95% confidence interval, 0.86 to 1.21). The estimated 7-year cumulative rates of disease-related death were 18% and 15% in the two groups, respectively (P = 0.24). CONCLUSIONS Intermittent androgen deprivation was noninferior to continuous therapy with respect to overall survival. Some quality-of-life factors improved with intermittent therapy. (Funded by the Canadian Cancer Society Research Institute and others; ClinicalTrials.gov number, NCT00003653.)

show abstract

mentioning

confidence: 99%

Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy

et al. 2012

View full text Add to dashboard Cite

show abstract

“…5 Detectable MMTV env gene-related antigenic reactivity was found in tissue sections of breast cancer, 6 -10 breast cancer cell lines, 11 serum, 12,13 pleural effusion 14 and lymph nodes. 15 Moreover, sequence homology to MMTV has been found in human DNA. 1,2,16 -21 Two studies detected the env gene of MMTV in 37-38.5% of breast tumor tissues but only in 0 -2% of normal tissues.…”

Section: Dear Sirmentioning

confidence: 99%

Mouse mammary tumor‐like env gene as a molecular marker for breast cancer?

Zangen

Harden

Cohen

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

Dear Sir,The involvement of the mouse mammary tumor virus (MMTV) in breast cancer has long been postulated but never proven. Two studies have detected the sequence of the MMTV env gene in more than one-third of breast tumor tissues. 1,2 The present study was designed to investigate whether this viral sequence could serve as a molecular marker for the detection of breast cancer. We amplified the viral sequence in 2 cell lines and 18 breast tumor samples, using PCR, PCR Southern hybridization and real-time PCR. Surprisingly, we could not detect the viral sequence in any of these samples despite amplification in positive controls. Our study calls into question the role of MMTV in human breast cancer tumorigenesis.The involvement of retroviruses in human cancer was established long ago, e.g., HPV in cervical and oropharyngeal tumors. 3,4 The participation of a virus similar to MMTV in human breast cancer has long been postulated but never demonstrated. Several lines of evidence suggested the involvement of MMTV-like retroviruses in human breast cancer. Previously, it was shown that MMTV is an agent associated with a high incidence of breast cancer in mice. 5 Detectable MMTV env gene-related antigenic reactivity was found in tissue sections of breast cancer, 6 -10 breast cancer cell lines, 11 serum, 12,13 pleural effusion 14 and lymph nodes. 15 Moreover, sequence homology to MMTV has been found in human DNA. 1,2,16 -21 Two studies detected the env gene of MMTV in 37-38.5% of breast tumor tissues but only in 0 -2% of normal tissues. 1,2 According to these studies, this viral sequence was highly specific to breast tumor tissues and was not detected in other tumor tissues.The present study was designed to examine whether the env gene of MMTV could be used as a molecular marker for the detection of breast cancer. We planned to evaluate, by real-time PCR, a panel of normal tissues, tumor breast tissues and blood samples from 40 breast cancer patients. MMTV env gene plasmid and MCF-7 and MB-MDA-231 cell lines were used as a positive control, as described in previous studies. 1,2,11,17 The viral sequence was first amplified by regular PCR; then, PCR products were hybridized with an internal probe by PCR Southern hybridization; finally, real-time PCR was performed. We were unable to detect the viral sequence in the cell lines or in the breast tumor tissues despite robust amplification from the plasmid control. MATERIAL AND METHODS Cell lines and tumor tissuesThe MCF-7 and MB-MDA-231 cell lines were purchased from the ATCC (Manassas, VA) and grown in RPMI medium with FBS 10%, penicillin and streptomycin 1%.Eighteen invasive ductal carcinomas of the breast from 17 patients were collected at the

show abstract

“…After a 5-day exposure to pokeweed mitogen (GIBCO Laboratory, Grand Island Biological Co), the lymphocytes were fused with the GM4672 human lymphoblastoid cell line according to a method described previously. 24 After fusion, the cells were seeded onto 96-well tissue culture plates (Nunc-Immunol), with hypoxanthine aminopterin thymidine selection media for 4 to 5 weeks. The clones were screened for binding to ␤2GPI with the modified aCL ELISA.…”

Section: Production Of Human Mabsmentioning

confidence: 99%

Differential Effects of Anti–β ₂ -Glycoprotein I Antibodies on Endothelial Cells and on the Manifestations of Experimental Antiphospholipid Syndrome

et al. 1998

Self Cite

View full text Add to dashboard Cite

Background-The antiphospholipid syndrome (APS) entails a prothrombotic state associated with the presence of anticardiolipin antibodies (aCL). aCL were shown to promote endothelial cell and platelet activation and to induce an APS-like syndrome in mice when administered intravenously. Recent data suggest that aCL target the plasma cofactor ␤ 2 -glycoprotein I (␤2GPI) rather than negatively charged phospholipids. However, it has not been determined whether different epitope-specific anti-␤2GPI antibodies obtained from one patient possess pathogenic properties. Methods and Results-Three ␤2GPI-binding IgM monoclonal antibodies (mAbs) (ILA-1, ILA-3, and ILA-4) were cloned from a patient with APS. The three antibodies were shown to bind ␤2GPI immobilized on irradiated plates, yet only ILA-1 bound ␤2GPI coated onto nonirradiated plates. Furthermore, when using the anti-␤2GPI enzyme-linked immunosorbent assay, ILA-1 was the only mAb inhibited by fluid phase ␤2GPI.

show abstract

Human monoclonal antibodies derived from lymph nodes of a patient with breast carcinoma react with MuMTV polypeptides

Cited by 21 publications

References 25 publications

Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy

Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy

Mouse mammary tumor‐like env gene as a molecular marker for breast cancer?

Differential Effects of Anti–β ₂ -Glycoprotein I Antibodies on Endothelial Cells and on the Manifestations of Experimental Antiphospholipid Syndrome

Contact Info

Product

Resources

About

Human monoclonal antibodies derived from lymph nodes of a patient with breast carcinoma react with MuMTV polypeptides

Cited by 21 publications

References 25 publications

Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy

Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy

Mouse mammary tumor‐like env gene as a molecular marker for breast cancer?

Differential Effects of Anti–β 2 -Glycoprotein I Antibodies on Endothelial Cells and on the Manifestations of Experimental Antiphospholipid Syndrome

Contact Info

Product

Resources

About

Differential Effects of Anti–β ₂ -Glycoprotein I Antibodies on Endothelial Cells and on the Manifestations of Experimental Antiphospholipid Syndrome